Stelara ustekinumab: Additional Phase III data

Additional data from the double-blind Phase III PSUMMIT I trial in 615 patients with active psoriatic arthritis showed that Stelara given every 12 weeks as maintenance therapy for 28 weeks produced ACR20 response rates of 55.7% in the 45 mg Stelara arm and 60.3% in the 90 mg dose arm. In patients who crossed over from placebo to receive induction therapy with 45 mg Stelara at weeks 24 and 28, followed by maintenance therapy every 12 weeks, the ACR20 response rate was 65.2%. Additionally, Stelara increased ACR50 response rates to 31.4% at week 52 from 24.9% at week 24 in the low-dose arm and to 37% at week 52 from 27.9% at week 24 in the high-dose arm. Furthermore, ACR70 response rates increased to 18% at week 52 from 12.2% at week 24 in the low-dose arm and to 21.2% at week 52 from 14.2% at week 24 in the high-dose arm. ...